The dissemination of extended-spectrum β-lactamase (ESBL)-producing bacteria presented a great concern worldwide. Gram-negative organisms such as Escherichia coli and Klebsiella pneumoniae are the most frequently isolated pathogens responsible for nosocomial infections. Objectives: The aim of this study was to investigate and to follow the emergence of resistance and the characterization of Extended-Spectrum Beta-Lactamases (ESBL) among broad-spectrum beta-lactam-Escherichia coli clinical isolates recovered from the military hospital and Habib Thameur hospital in Tunisia. Methods: A total of 113 E.coli isolates obtained during the period 2004 through 2012 showed a significant degree of multi-resistance. Among these strains, the double-disk synergy test confirmed the ESBL phenotype in 46 isolates. These included 32(70%) strains from Hospital A and 14(30%) from Hospital B. Results: The ESBL was identified as CTX-M-15. The ESBL resistance was transferred by a 60 kb plasmid CTXM-15-producing isolates were unrelated according to the PFGE analysis and characterization of the regions surrounding the blaCTX-M-15 showed the ISEcp1 elements located in the upstream region of the bla gene and 20 of them truncated by IS26. Conclusion: ESBL producing E. coli strains are a serious threat in the community in Tunisia and we should take into consideration any possible spread of such epidemiological resistance.
Introduction
The production of extended-spectrum β-lactamases continues to be the important cause of resistance among gram negative bacteria. The TEM-and SHV-are the first ESBLs type, mutant derivatives of established plasmid-mediated β-lactamases , however , a novel type of plasmid mediated ESBLs, the CTX-M enzymes, cefotaximases, emerged worldwide in the last decade, and preferentially hydrolyze cefotaxime over ceftazidime and are inhibited by clavulanic acid, sulbactam, and tazobactam 1 were reported in the second half of the 1980s classified in Ambler class A and in group 2be of the Bush, Jacoby and Medeiros classification 2 . More than 65 CTX-M β-lactamases were revealed worldwide. The phylogenic study clustered them in five major groups: CTXM 1,-2, -8, -9, and -25 groups [3] [4] [5] .
The number of reports studing the CTX-M variants continue to increase,CTX-M-28 enzyme was recently reported in Tunisa 6, 7 . CTX-M-9, first described in 1994 in Spain 8 , Guyana and the United Kingdom 9 also in Tunisa 10 . Also, in 2006, Boyd et al mention the first report of CTX-M-16 type-producing Enterobacteriaceae in Tunisia and in Africa 11 . Another variant of CTX-M type, CTX-M-8 was detected in cefotaxime-resistant Proteus mirabilis strain in association with a plasmid mediated AmpC lactamase 12 . CTX-M-15 is the most prevalent ß-lactamase detected amongst the ESBL-positive K. pneumoniae and E. coli strains derived from CTX-M-3 by a substitution of Asp-240-Gly which increases its catalytic efficiency against ceftazidime 13, 14 first described in 2001 15, 16 Many reports have documented the emergence of CTX-M gene 9 , and the first report of the CTX-M-15 in Tunisia was cited in the Charles Nicolle Hospital in 1984 and it was described in various studies in Tunisia including that of coque et al, the gene has been found in E. coli strains in a Tunisian Hospital 17 , France 18 , and Central African Republic [19] [20] [21] [22] [23] [24] [25] .91% of the ESBL-producing isolates carried blaCTX-M-15 genes 21 .
The production of CTX-M enzymes is an emerging phenomenon that has been called 'the CTX-M pandemic' 16 .
The insertion sequence ISEcp1 was found to be involved in the mobility of blaCTX-M,was located upstream the bla CTX-M-27 gene e in a neonatal ward of the maternity department of Farhat Hached Hospital, Sousse 26 .It has been found also upstream the CTX-M-14 producing E. coli isolated from hospitalized patients in a university Hospital of Tunisia 27 ., and upstream the CTX-M-15 gene in Proteus mirabilis and Morganella morganii isolated at the Military Hospital of Tunis 24 . ISEcp1 was located upstream of the blaCTX-M gene on E. coli isolates from food samples 28 . CTX-M genes may spread through clonal dissemination or horizontal gene transfer 19 .
Methods

Bacterial strain
These clinical strains were isolated from samples collected in different wards, including the emergency ( All the isolates were identified by the Vitek automated system (bioMérieux, Vitek 32) and API 20E system (bioMérieux, Marcy l'Etoile, France).
E. coli DH5a (recA1, F_, end A1, gyrA96, thi-1, hsdR17, rK_, mK+, supE44, relA1, DlacU69, F80lazDM15) and E. coli HB101 (F_, D(gpt-proA) 62, leuB6, supE44, ara-14, galK2, lac Y1, D(mcrc-mrr), rps, L26, Xyl-rmtl 1, thi-1, IncFI, rec AB, strr), were used respectively for the transformation and conjugation experiments.
Antimicrobial susceptibility and synergy testing
Routine antibiograms were determined by the disk diffusion method on Mueller-Hinton agar (MH, Diagnostics Pasteur) using susceptibility breakpoints as recommended by the Clinical and Laboratory Standards Institute (CLSI) 29 .
The double-disk synergy test was used to detect the ESBL production as previously described 30, 24 by using amoxicillin-clavulanate against cefotaxime, ceftriaxone, ceftazidime and aztreonam. Minimum inhibitory concentrations (MICs) of selected anti-microbial agents were determined by using the dilution method on Mueller-Hinton agar according to CLSI guidelines 29 . Table 1 shows MICs (µg/mL) of various antimicrobial agents obtained for the clinical isolate E. coli, transconjugant and transformant, and the E. coli recipients. CTX, cefotaxime; CRO, ceftriaxone; CAZ, ceftazidime; ATM, aztreonam; TIC, ticarcillin; STR, streptomycin; IMP, imipenem; ERT, ertapenem; CHL, chloramphenicol; TET, tetracycline; OFX, ofloxacin. NM, not measured.
β-Lactamase extraction and isoelectric focusing IEF was performed as described previously 17, 31 , using a culture grown overnight at 37°C in Trypto-Caseine Soy broth (TCS). These exponentially growing bacteria were harvested at 17,400 _ g (Rotor F 0650, Bekman) and bacterial suspensions were prepared by sonication in UP 400 S (dv. Hielscher, Germany) five times for 45 s each time.
Crude extract was centrifuged at 17,400 _ g (Universel 32 R, Hettich) for 15 min at 4°C. The supernatant of the sonicate was subjected to isoelectric focusing on ampholine polyacrylamide gel with a pH range of 3-10 at a voltage range of 100-300, at 4 o C in a 111Mini IEF Cell (Bio-Rad). TEM-1 (pI 5.4), TEM-2 (pI 5.6), TEM-3 (pI 6.3), SHV-1 (pI 7.6) and SHV-12 (pI 8.2) were used as pI markers.
β-lactamase activities were revealed by iodemetric method using benzylpenicillin to 1 mM and cefotaxime (3 mM) as substrates in phosphate buffer (25 mM; pH 7).
β-Lactamase assay
Hydrolytic activities of crude extracts for β-lactam antibiotics were determined by the spectrophotometric method at the wave length of maximal absorbance for the β-lactam ring of each antibiotic. 32 The decrease in absorbance of the antibiotics at an appropriate concentration was measured in a temperature controlled spectrophotometer (Varian R CARY 50 Bio UV-visible) at 37°C. Specific activity is calculated on depending of Ross and O'Callaghan equation in 1975 33
Effect of inhibitors (IC50 determination)
Crude enzyme extract was incubated with clavulanic acid and sulbactam increasing concentrations. EDTA was used at a fixed concentration of 1 mM. Residuals β-lactamases activities were determined by the spectrophotometric method using cephalothin 1 mM as substrate. The inhibitor concentration required to inhibit 50% of enzyme activity was determined graphically (IC50) 34 .
Analysis of plasmids and transfer of resistance
Plasmid DNA was extracted with the alkaline lysis method, as described by Sambrook et al 35 .
Conjugation experiments were carried out with E. coli HB101, as previously described 7, 24 . (31; 9;3;4). The transconjugants were selected on LB agar supplemented with streptomycin (100 μg/ml) and ampicillin (100 μg/ml).
Transformation experiments were carried out by using E. coli DH5α as the recipient as previously described 31, 36 . Transformants were selected on Luria-Bertani medium agar plates supplemented with ampicillin (100 mg/ml). Transformants were subjected to DDST to confirm the presence of ESBL genes and were examined for co-transfer of other antibiotic resistance determinants present in the donor clinical isolates by disk diffusion.
Characterization of the resistance genes using PCR method and sequencing
Primers used for amplification of resistance genes, annealing temperatures and predicted amplicon sizes are shown in Table 1 . They were used to detect blaCTX-M, blaSHV, blaTEM and the sequences surrounding the bla CTX-M gene, ISEcp1and IS26 37,38 also the aac(6')-ib-cr gene. The DNA amplification programs consisted of initial denaturation for 5 min at 94°C, followed by 30 cycles of denaturation for 30 s at 94°C, annealing temperatures differed according to the primer pair used and were for 45 s at 57°C for the blaCTX-M and blaISEcp1; 55°C for blaTEM and blaSHV. Finally, the polymerization for 5 min at 72°C.
PCR products were purified using QIAquick PCR Purification Kit (Qiagen, USA) and sequenced using the Big-Dye Terminator v.3.1 Cycle Sequence Kit and ABI Prism 310 automatic sequencer (Applied Biosystems, USA).
The nucleotide sequences were compared with those included in the GenBank database using BLAST (http:/ www.ncbi.nlm.nih.gov/blast/).
Detection of ISEcp1
PCR for ISEcp1 was used to examine the region upstream of the the blaCTX-M gene with the primers shown in Table 1 . An annealing temperature,57 o C was used followed by sequencing of the PCR product. 39 .
Typing of isolates by MLST
Molecular typing using Pulsed-field gel electrophoresis (PFGE)
The epidemiological relationship of CTX-M-15 positive strains was studied by PFGE using XbaI as restriction enzymes (Bio-Rad Laboratories, France). Restriction fragments of DNA were separated by electrophoresis which was performed in a 1.2% agarose gel on a CHEF DRIII apparatus (Bio-Rad Laboratories, Richmond, CA, USA) with 6V/cm for 19 h at 14ºC with an initial switch time of 2.2 to 52.0 sec. XbaI-digested DNA were compared visually based on differences in the number and mobility of bands 40 .
Results
Studied strains show multidrug resistance phenotype with various antibiotics. They were highly resistant to antibiotics such as penicillins, cephalosporins, aminoglycosides, quinolones and tetracycline, (MIC 512-64µg/mL) whereas remained susceptible to imipinem (MIC <2µg/ ml) and meropenem (MIC <0,5µg/ml) ( Table 2 ). Similar results were observed with the transformants and transconjugants except with quinolones, phenicol and aminoglycosides, suggesting that this resistance could be in chromosome. 46 E. coli strains were phenotypically confirmed as ESBL with the double disc synergy showing a marked synergy between ceftazidime, céfotaxime, aztreonam, ceftriaxoneand amoxicillin-clavulanic acid on MH agar plates as well as the transformants and transconjugants suggested the presence of a class A ESBL. The resistance to expanded-spectrum cephalosporins was successfully transferred to a recipient strains, E. coli HB101 with the frequency of transfer equivalent to 5× 10 -5 transconjugant/recipient and this indicated that the gene was plasmidic transferred with an estimated molecular size of 60 kb of the transferable plasmid.
An extended-spectrum β-lactamase band with a pI 8.6 with cefotaxime as substrate was detected in the 46 ESBL strains (Figure 1 ), transformants and transconjugants.
Kinetics resuts showed that E. coli strains hydrolyze benzylpenicillin, ticarcillin with a high level of hydrolytic activity, specific activities ranged between (8.77-6.67U/mg of protein) and hydrolyze cephalosporins with a higher hydrolytic activity to cefotaxime (U/mg of protein) ( Table 3 ). -1 (pI 5.4), TEM-2 (pI 5.6),  TEM-3 (pI 6.3), SHV-1 (pI 7.6 ) and SHV-12 (pI 8.2) These enzymes are not inhibited by EDTA and are not defined as metallo-enzymes. The analysis of the IC50 showed that the clavulanic acid with IC50 of 3.5 µM was the powerful inhibitor and categorized this enzyme to class A: serine active β-lactamases ( (Figure 2 ) showed that the 46 strains presented different profiles, and our studied strains were unrelated suggesting that the dissemination of bla CTX-M-15gene among E. coli clinical strains due to horizontal transfer of multi-resistance or/and the genetic mobile element are responsible for the dissemination of these gene.
Discussion
Our study investigated the genetic environment of blaC-TX-M genes in fourty six Escherichia coli extended spectrum β-lactamase (ESBL)-positive isolates. Of these 46 strains, 10 E. coli isolates (24 %) produced ß-lactamase activities with a varied isoelectric points (pIs) between 5.5 and 8,6 (lane 1,5 and 6, Figure 1 ), they carried the blaTEM gene (9 from hospital A and 1 from hospital B).
Sequencing of PCR products of this latter showed that it corresponded to the TEM- The presence of the insertion sequence ISEcp1upstream the gene in all the CTX-M-15 strain producers is a real concern which plays an important role of the mobilization of this latter as has been reported in several studies 16, 41 .
According to the MLST analysis of one E. coli isolate, it showed that this belonged to ST 131, displays specific O25 type (O 25b) and the E. coli isolate belonged to the B2 phylogenetic subgroup I. This phylogroup B2 ST131 is previously described on E.coli CTX-M producers responsible for the clonal diffusing of the CTX-M-15 gene 41, 42 and this isolate may belong to this clone. The presence of the blaCTX-M-15 encoding gene amongst unrelated strains argued for genetic transit of mobile elements amongst unrelated strains. Our study confirms that the CTX-M-15 gene is the most prevalent ESBL found in Tunisian hospitals and the association of the bla CTX-M-15 with the insertion sequence ISEcp1 facilitates its dissemination.
In short with reference to our insightful study, we should control the emergence of ESBL producing E. coli strains from hospitals environment which in some cases lack both the efficient surveillance and cleaning services. This finding is alarming for healthcare providers and reinforces other previous studies in Tunisia to prevent a further spread and in the light of the current and fabulous medical breakthroughs, that we are now witnessing on a daily basis of, has to be a wake-up call for us to further enhance our efforts and better our practical measures.
